Background
==========

Breast cancer is the most common cancer in female patients and is the leading cancer type in Taiwan. The majority of breast cancers are invasive ductal and lobular carcinomas. Pure mucinous carcinoma (MC) is a relatively rare histological type of breast cancer and accounts for 1% to 7% of all invasive mammary cancers \[[@B1],[@B2]\]. MC of the breast is characterized by a mucinous morphology in over 90% of the tumor. This subtype of patients has some features that differ from those of patients with infiltrating ductal carcinoma not otherwise specified (IDC). MC has a lower incidence of nodal involvement, favorable histological grade and higher estrogen receptor (ER) and progesterone receptor (PR) \[[@B3]\] expression, and usually occurs in women aged over 60 years \[[@B4]\]. The diagnosis of MC of the breast has a favorable prognosis and has shown excellent long-term survival in a previous study \[[@B5]\].

Because of its rarity, most studies on MC of the breast have fewer case numbers, and information on MC after long-term follow up is limited. There is still controversy about the prognostic factors of MC of the breast. The literature recommends that this subtype of cancer should be treated less aggressively than IDC. However, the evidence of previous studies is weak due to the small sample size and short-term follow up.

The health policy for breast cancer screening has evolved since 1995 in Taiwan. With the increasing incidence of breast cancer, the incidence of patients with a sparse tumor has also increased. Therefore, greater understanding about these rare tumors is urgent. The aims of this study were to investigate the incidence rate, treatment patterns, and prognostic factors of MC, and the long-term clinical outcomes compared with IDC in middle and south Taiwanese women.

Methods
=======

In this study, we retrospectively reviewed the data on 2,767 breast cancer patients treated at Changhua Christian Hospital and National Cheng Kung University Hospital, Taiwan, between November 1996 and August 2009. Of this group, 93 patients who presented with MC and 2,674 with IDC were identified from the cancer registry database. The data before 1996 were excluded due to incomplete information on hormone receptor status. This study was approved by the institutional review board and ethics committee of our hospital. The medical records of patients with MC were reviewed. MC of the breast was defined in our hospital as having a mucin component of more than 90% of the lesion. The American Joint Committee on Cancer (AJCC) staging system was used in this study. The clinical baseline data, including demographic characteristics (for example, age), tumor features (for example, stage, tumor size, nodal involvement, histological grade, lymphovascular invasion, ER, PR and HER2 status) and treatment patterns (for example, primary treatment and systemic therapy) were collected. Survival time was defined as the time from pathologic diagnosis to the most recent patient status or database update. Distant and loco-regional recurrences were defined as clinical evidence of distant and local tumor recurrence. All patients were treated according to our breast cancer guidelines (based on the National Comprehensive Cancer Network (NCCN) \[[@B3]\] and/or St Gallen guidelines). Overall survival and disease-free survival was calculated at 10 years of follow up. The prognostic risk of age at diagnosis, tumor size, stage, histology grade, ER, PR, and HER2 status, primary treatment and systemic therapy was calculated by multivariate and univariate analysis. The clinicopathologic characteristics and survival data of MC were reviewed and compared with those of IDC.

Analysis of variance (ANOVA) was used for the comparison of continuous variables, and categorical variables were normally tested by the χ^2^ test when appropriate. Data are expressed as the mean ± SD for continuous variables. All *P-*values were two-tailed; a *P-*value less than 0.05 was considered to indicate statistical significance. Cox logistic regression was conducted for multivariate analysis. The Kaplan-Meier method was used for cumulative survival rates, and differences in cumulative survival were assessed using the log-rank method. The SAS 9.1.3 for Windows software package was used for analysis (SAS Institute Inc., Cary, NC, USA).

Results
=======

From 1996 to 2009, a total of 93 patients with MC of the breast were identified in our database. At the same time, 2,674 patients with IDC were also identified. The incidence of MC of the breast in our study was 3.4% (93 of 2,767) of breast cancer cases. The clinicopathologic characteristics of all patients are summarized in Table  [1](#T1){ref-type="table"}. Mean age at diagnosis and tumor size was not statistically significantly different in the MC and IDC cases. The majority of MC was early stage (89%); only nine patients were at the advanced stage. Expression of the hormonal receptors, ER and PR, was higher in MC than in IDC. MC also presented with lower HER2/neu gene overexpression and less axillary lymph node involvement and lymphovascular invasion.

###### 

Characteristics of patients with mucinous carcinoma and infiltrating ductal carcinoma

                                                                                      **MC (n = 93)**   **IDC (n = 2,674)**   ***P***
  --------------------------------------------- ------------------------------------- ----------------- --------------------- ---------
  Age, years,                                                                                                                 
                                                mean (SD)                             49.77 (13.76)     50.68 (11.39)         0.529
                                                median                                45.88             49.22                  
                                                range                                 28, 85            15, 89                 
  Tumor size, cm,                                                                                       0.185                 
                                                mean (SD)                             3.06 (2.55)       2.69 (1.65)            
                                                median                                2.50              2.30                   
                                                range                                 0.20, 17.0        0.10, 15.0             
  Tumor stage, n (%),                                                                                   0.480                 
                                                T1                                    29 (34.12)        1123 (42.00)           
                                                T2                                    47 (55.29)        1297 (48.50)           
                                                T3                                    7 (8.24)          178 (6.66)             
                                                T4                                    2 (2.35)          76 (2.84)              
                                                unknown or other                      8                 0                      
  Grade, n (%),                                                                                         \<0.0001              
                                                I                                     22 (66.67)        251 (14.13)            
                                                II                                    11 (33.33)        994 (55.97)            
                                                III                                   0 (0)             531 (29.90)            
                                                unknown or other                      60                898                    
  Lymphovascular invasion, n (%),                                                                       \<0.0001              
                                                present                               10 (15.38)        996 (47.41)            
                                                absent                                55 (84.62)        1105 (52.59)           
                                                unknown or other                      28                573                    
  ER status, n (%),                                                                                     \<0.0001              
                                                positive                              84 (90.32)        1715 (65.28)           
                                                negative                              9 (9.68)          912 (34.72)            
                                                unknown or other                      0                 47                     
  PR status, n (%),                                                                                     \<0.0001              
                                                positive                              74 (79.57)        1555 (59.19)           
                                                negative                              19 (20.43)        1072 (40.81)           
                                                unknown or other                      0                 47                     
  HER2/neu gene overexpression status, n (%),                                                           0.023                 
                                                positive                              8 (9.88)          467 (19.95)            
                                                negative                              73 (90.12)        1874 (80.05)           
                                                unknown or other                      12                333                    
  Lymph node status, n (%),                                                                             \<0.0001              
                                                positive                              17 (19.77)        1144 (43.73)           
                                                negative                              69 (80.23)        1472 (56.27)           
                                                not evaluated                         7                 58                     
  Primary treatment, n (%),                                                                             0.660                 
                                                mastectomy                            59 (64.84)        1735 (67.27)           
                                                lumpectomy with RT                    30 (32.97)        751 (29.12)            
                                                lumpectomy without RT                 2 (2.20)          93 (3.61)              
                                                no surgery                            2                 95                     
  Systemic therapy, n (%),                                                                              \<0.0001              
                                                endocrine therapy alone               37 (44.05)        523 (21.02)            
                                                chemotherapy alone                    6 (7.14)          603 (24.24)            
                                                endocrine therapy with chemotherapy   41 (48.81)        1362 (54.74)           
                                                none                                  8                 186                    
                                                unknown                               1                 0                      
  Follow up time, months                                                                                                      
                                                median                                56                55                     
                                                range                                 1.97-142          0.30-142               
  10-year overall survival rate                 0.9447                                0.8611            0.042                 

*MC* pure mucinous carcinoma, *IDC* infiltrating ductal carcinoma, *ER* estrogen receptor, *PR* progesterone receptor, *RT* radiotherapy.

The primary treatment pattern of the MC patients was similar to that of the IDC patients. The majority of patients (65% in the MC group and 68% in the IDC group) received mastectomy. Two patients in the MC group and 95 in the IDC group did not undergo surgery. In terms of systemic therapy, more MC patients received endocrine therapy alone because more of these patients were hormonal receptor-positive and had a favorable histology grade. On the other hand, IDC patients received more chemotherapy than MC patients (79% vs 56%).

The mean follow up time for the MC and IDC patients was 56 months (range 2.0 to 142.0) and 55 months (range 0.3 to 142.0), respectively. The 10-year overall survival rate was 94.5% vs 86% for the MC and IDC patients, respectively (*P* = 0.042) (Figure  [1](#F1){ref-type="fig"}), indicating MC had a better long-term outcome than IDC, with statistical significance; there were six disease relapses and five deaths during the period of follow up. Univariate analysis for disease-free survival and overall survival based on clinicopathologic features in the MC group revealed no significant factors for survival (Table  [2](#T2){ref-type="table"}). More than 80% of MC patients were hormonal receptor-positive (Table  [1](#T1){ref-type="table"}). In early MC breast cancer (stages I and II), the 10-year disease-free survival rate and the 10-year overall survival rate of the patients treated with hormone therapy only were both higher than those of patients treated with hormone therapy and chemotherapy, although neither was statistically significantly different (*P* = 0.529 and *P* = 0.156) (Table  [3](#T3){ref-type="table"}). As shown in Table  [4](#T4){ref-type="table"}, among the 45 patients with stage II MC, 30 patients were treated with hormone therapy plus chemotherapy and 15 with hormone therapy alone. After long-term follow up, only two deaths were noted in the hormone therapy plus chemotherapy group.
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###### 

Univariate analysis of disease-free survival and overall survival of patients with pure mucinous carcinoma

                                                                    **Disease-free survival**   **Overall survival**         
  ----------------------------------------------------------------- --------------------------- ---------------------- ----- -------
  Age, years                                                        \>1                         0.603                  \<1   0.329
  Tumor size, cm                                                    \<1                         0.717                  \>1   0.999
  Grade, I vs II                                                    NA                          0.998                  NA    NA
  Lymphovascular invasion (present vs absent)                       NA                          0.998                  NA    0.999
  ER (positive vs negative)                                         \<1                         0.139                  \<1   0.997
  PR (positive vs negative)                                         \<1                         0.580                  \<1   0.343
  HER2 (positive vs negative)                                       \>1                         0.122                  \<1   0.998
  Lymph node status (positive vs negative)                          NA                          0.997                  NA    0.998
  Primary treatment (mastectomy vs lumpectomy with RT)              \<1                         0.996                  \<1   0.997
  Primary treatment (mastectomy vs lumpectomy without RT)           \<1                         0.997                  \<1   0.998
  Systemic therapy (endocrine therapy alone vs with chemotherapy)   \>1                         0.746                  NA    NA

*ER* estrogen receptor, *PR* progesterone receptor, *RT* radiotherapy, *NA* not applicable.

###### 

Characteristics of patients with early-stage (I and II) pure mucinous carcinoma of the breast

                                    **Endocrine therapy**   ***P***                        
  --------------------------------- ----------------------- -------------- --------------- ---
  Age, years,                                                              \<0.0001        
                                    mean (SD)               43.85 (7.53)   58.15 (15.62)    
                                    median                  44.54          59.54            
                                    range                   28, 68         28, 85           
  Tumor size, cm,                                                          0.059           
                                    mean (SD)               3.42 (2.62)    2.39 (1.93)      
                                    median                  3.0            2.0              
                                    range                   0.20, 17.0     0.20, 12.0       
  Tumor stage, n, (%),                                                     \<0.0001        
                                    T1                      5 (13.51)      19 (52.78)       
                                    T2                      28 (75.68)     15 (41.67)       
                                    Unknown or other        8              3                
  grade, n (%),                                                            1.000           
                                    I                       11 (73.33)     8 (66.67)        
                                    II                      4 (26.67)      4 (33.33)        
                                    Unknown or other        26             25               
  Stage, n (%)                                                             \<0.0001        
                                    I                       4 (11.76)      19 (55.88)       
                                    II                      30 (88.24)     15 (44.12)       
  Lymphovascular invasion, n (%),                                          0.018           
                                    present                 7 (28)         1 (3.33)         
                                    absent                  18 (72)        29 (96.67)       
                                    unknown or other        16             7                
  ER status, n (%),                                                        0.112           
                                    positive                35 (85.37)     36 (97.30)       
                                    negative                6 (14.63)      1 (2.70)         
  PR status, n (%),                                                        0.233           
                                    positive                32 (78.05)     33 (89.19)       
                                    negative                9 (21.95)      4 (10.81)        
  HER2 status, n (%),                                                      0.199           
                                    positive                5 (14.29)      1 (3.03)         
                                    negative                30 (85.71)     32 (96.97)       
                                    unknown or other        6              4                
  Lymph node status, n (%),                                                0.013           
                                    positive                11 (28.21)     2 (5.56)         
                                    negative                28 (71.79)     34 (94.44)       
                                    not evaluated           2              1                
  Primary treatment, n (%),                                                0.056           
                                    mastectomy              31 (77.50)     20 (54.05)       
                                    lumpectomy with RT      8 (20)         16 (43.24)       
                                    lumpectomy without RT   1 (2.50)       1 (2.70)         
                                    no surgery              1              0                
  Follow up time, months                                                                   
                                    median                  63             46               
                                    range                   3, 139         9, 142           
  10-year disease-free survival     87.90%                  92.86%         0.529           
  10-year overall survival rate     88.82%                  100%           0.156           

*ER* estrogen receptor, *PR* progesterone receptor, *RT* radiotherapy.

###### 

Characteristics of patients with stage II pure mucinous carcinoma of the breast

                                                         **Endocrine therapy**   ***P***         
  --------------------------------- -------------------- ----------------------- --------------- ---
  Age, years                                                                     0.001           
                                    mean (SD)            43.43 (6.17)            61.16 (16.89)    
                                    median               44.68                   64.20            
                                    range                31.0, 57.0              28.0, 84.0       
  Tumor size, cm                                                                 0.772           
                                    mean (SD)            3.60 (2.89)             3.34 (2.43)      
                                    median               3.0                     2.8              
                                    range                0.20, 17.0              2.0, 12.0        
  Tumor stage, n (%),                                                            0.545           
                                    T1                   2 (7.14)                0 (0)            
                                    T2                   26 (92.86)              14 (100)         
                                    unknown or other     2                       1                
  Grade, n (%),                                                                  1.000           
                                    I                    9 (81.82)               3 (75)           
                                    II                   2 (18.18)               1 (25)           
                                    unknown or other     19                      11               
  Lymphovascular invasion, n (%),                                                0.624           
                                    present              4 (21.05)               1 (8.33)         
                                    absent               15 (78.95)              11 (91.67)       
                                    unknown or other     11                      3                
  ER status, n (%),                                                              1.000           
                                    positive             28 (93.33)              14 (93.33)       
                                    negative             2 (6.67)                1 (6.67)         
  PR status, n (%),                                                              0.695           
                                    positive             23 (76.67)              13 (86.67)       
                                    negative             7 (23.33)               2 (13.33)        
  HER2 status, n (%),                                                            1.000           
                                    positive             1 (3.70)                1 (7.14)         
                                    negative             26 (96.30)              13 (92.86)       
                                    unknown or other     3                       1                
  Lymph node status (%)                                                          0.396           
                                    positive             6 (20)                  1 (6.67)         
                                    negative             24 (80)                 14 (93.33)       
  Primary treatment, n (%),                                                      1.000           
                                    mastectomy           23 (76.67)              11 (73.33)       
                                    lumpectomy with RT   7 (23.33)               4 (26.67)        
  Follow up time, months                                                                         
                                    median               57                      43               
                                    range                3, 139                  12, 86           
  10-year disease-free survival     87.69%               75%                     0.637           
  10-year overall survival rate     88.44%               100%                    0.424           

*ER* estrogen receptor, *PR* progesterone receptor, *RT* radiotherapy.

Discussion
==========

MC of the breast is uncommon, comprising approximately 4% (range 1% to 7%) of all invasive breast cancers. MC has better prognosis (90% survival at 10 years) and higher incidence in perimenopausal and postmenopausal age groups. The incidence of MC in women under 35 years of age is only 1% \[[@B1],[@B6]-[@B8]\]. MC is a slow-growing tumor, with an estimated growth rate of one third of that of IDC. MC shows fewer axillary lymph node metastases and more frequent ER expression, and has a low frequency of androgen receptor and low incidence of androgen receptor with ER and/or PR co-expression when compared to IDC \[[@B9]\]. Under ultrasonography, MC is commonly lobulated with homogeneous, iso-echoic and normal posterior acoustic appearances, but rarely has benign features on imaging \[[@B7],[@B8]\].

The majority of MC (89%) presented at the early stages (I and II) with favorable clinicopathologic features. However, the mean age at diagnosis of MC was 49.8 years in this study, which was much younger than in a study of Western women \[[@B10]\]. Many previous studies have reported that MC was more frequently diagnosed in women older than 70 years. However, the incidence of breast cancer in Taiwan has increased recently. The mean age of breast cancer diagnosis (49 years) was advanced by 10 years. There was a similar trend among the patients presenting with MC. The reason for the younger age at diagnosis among Taiwanese women is not clear, although there are some explanations. First, there are some physiological differences between women in the West and the East. In Asia, the breasts of women are smaller and denser. Most MC patients presented with palpable masses and the wide use of ultrasound made it easier to diagnose earlier in our country. Second, the health policy for breast cancer screening has evolved since 1995. Taiwanese women over 45 years old undergo mammography every 2 years. As a result, more middle-aged patients were shifted from the population. Third, dietary habits and environmental and genetic factors differ from Western countries. Because of the small number of reported cases, further studies related to the environmental, genetic and pathological features of Asian women are needed.

Previous studies have reported that MC had more favorable clinicopathologic characteristics than IDC \[[@B2],[@B4],[@B10],[@B11]\]. In our study, MC had a lower histologic grade, less lymphovascular invasion, higher hormonal receptor expression (ER and PR) and less HER2/neu gene overexpression. MC also demonstrated less axillary lymph node involvement than IDC, with a statistically significant difference. In addition, there were no significant differences in age, tumor size and pathologic stage. The 10-year survival rate of MC patients was 94.5%, which was statistically significantly better than the IDC survival rate. Our report ascertained favorable long-term outcomes for patients with MC. Previous studies also showed that MC was more frequently associated with hormone receptor expression \[[@B11],[@B12]\]; this was in concordance with our study, in which the positive rates for ER and PR were 90% and 80%, respectively. Hormone receptor-positive tumors were frequently associated with a well-differentiated histology pattern and were sensitive to adjuvant hormonal therapy. The long-term prognosis for MC was better than for IDC tumors. However, some investigators showed that breast IDC with a high level of hormone receptor expression was less sensitive to chemotherapy \[[@B13]-[@B15]\]. MC has been proven to be a hormone receptor-rich tumor and differs in tumor characteristics, including tumor behavior and response to treatment, from IDC. A genomic study confirmed that MC is an entity distinct from IDC, and that tumor behavior characterized by genetic aberrations is a luminal phenotype \[[@B16]\]. The St Gallen guideline for ER-positive breast cancer recommends that chemotherapy should not be administrated if the tumor is highly endocrine-responsive and has a low risk of recurrence. When planning systemic therapy for patients with MC, we should be concerned that ER-rich tumors are more likely to benefit from tamoxifen than from chemotherapy. When adding chemotherapy to endocrine-based adjuvant therapy, the benefit of systemic chemotherapy should be considered carefully in the treatment of these slow-growing tumors.

Axillary lymph node involvement has been known as an important prognostic factor in IDC. Bae *et al*. identify that MC is shown to have better disease-free survival than IDC, but it is similar in overall survival. They find that nodal status and adjuvant therapy seem to be more significant predictors of prognosis than histologic subtype \[[@B17]\]. Di Saverio *et al*. use tumor size as an independent prognostic indicator, but it was less significant compared to nodal status and age in MC cases \[[@B10]\]. Although we did not compare the DNA stemline of MC and IDC in our study, Toikkanen *et al*. have already found that nearly all MC has a normal diploid stemline that is different from that of common ductal carcinoma. Aneuploid tumors tend to be of higher grade and stage than diploid tumors \[[@B18]\]. Jambal *et al*. developed a human breast cancer cell line called BCK4, that can be the unique model to study the phenotypic plasticity, hormonal regulation, optimal therapeutic interventions and metastatic patterns of MC more clearly \[[@B19]\].

According to the treatment guidelines, adjuvant chemotherapy is indicated for IDC patients with lymph node metastases. However, lymph node involvement was not a good prognostic factor in our study. In our univariate and multivariate analysis of disease-free survival and overall survival of patients with MC, we found no pathologic features that were significant prognostic risk factors (Table  [2](#T2){ref-type="table"}). Adjuvant hormone therapy was adequate if the patients were hormone receptor-positive.

Tumor size in the AJCC staging system may not be a significant factor because mucin comprises the majority of the tumor volume \[[@B11]\]. According to the NCCN Clinical Practice Guidelines in Oncology \[[@B3]\], adjuvant endocrine therapy is indicated for tumors more than 3 cm in diameter and for MC patients with axillary lymph node metastasis, adjuvant endocrine therapy plus or minus chemotherapy should be considered. Further large-scale prospective studies are urgently needed to define the therapeutic guidelines for MC breast cancer.

Conclusions
===========

MC is a relatively rare type of breast cancer, occurring in about 3.5% of all newly diagnosed breast cancer patients in the middle and south of Taiwan. It has been associated with a better long-term prognosis than IDC. Our data confirm the less aggressive behavior of MC compared to IDC. MC had favorable clinicopathologic characteristics in terms of tumor grade, hormone receptor status and lymph node involvement.
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